Nanjing Legend Bio Completes $424 Million NASDAQ IPO; Shares Rise 60%
publication date: Jun 5, 2020
In a very successful debut offering, Nanjing Legend Biotech priced its US IPO above the expected range at $23 per ADS, raising $424 million. The company's ADS's climbed 60% higher to $36.60 in early trading, giving Legend a market capitalization of nearly $5 billion. In 2017, Legend announced its anti-BCMA CAR-T therapy produced a 94% overall response rate in myeloma patients. Six months later, Janssen formed a 50-50 partnership with the company for the CAR-T candidate in a $1 billion-plus deal, including $350 million upfront. More details....
Stock Symbol: (NSDQ: LEGN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.